{
    "clinical_study": {
        "@rank": "129719", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg\n      Tablets, taken twice daily is effective in reducing the red and white heads and overall\n      redness associated with rosacea."
        }, 
        "brief_title": "Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea", 
        "condition": "Acne Rosacea", 
        "condition_browse": {
            "mesh_term": [
                "Acne Vulgaris", 
                "Rosacea"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Healthy, post-pubescent male and females > age 18, with rosacea, 10 to 30, [papules\n             and pustules] and < 2 nodules.\n\n          -  Presence of moderate to severe erythema.\n\n          -  Presence of telangiectasia.\n\n          -  Female patients must utilize one of the following methods of birth control throughout\n             the study: IUD, diaphragm, a condom plus the use of a spermicidal gel or foam, oral\n             contraceptives (provided patient has been utilizing this method for at least 4 months\n             prior to baseline and has not changed the brand within this period).  Patients may\n             also participate if they are surgically sterilized, in a monogamous relationship with\n             a sterile partner, or sign an agreement that they will abstain from sexual\n             intercourse during the course of a study.\n\n          -  Patients must sign an informed consent form.\n\n          -  Negative pregnancy test and non-lactating.\n\n        Exclusion Criteria\n\n          -  The initiation of a hormonal method of contraception within 4 months of baseline; or\n             discontinuation during the course of study; or change in the actual product within 4\n             months of baseline or during the study.\n\n          -  The use of topical acne treatments within 2 weeks of baseline.\n\n          -  The use of systemic antibiotics within 4 weeks of baseline.\n\n          -  The use of an investigational drug with 90 days of baseline.\n\n          -  Pregnant women or women of child-bearing potential who are not using an adequate form\n             of birth control as described in Item 4 of the Inclusion Criteria.\n\n          -  Nursing women.\n\n          -  Patients with a known hypersensitivity to tetracyclines.\n\n          -  Patients on clinically significant, concomitant drug therapy (See section below).\n\n          -  The use of any acne treatment during the course of the study.\n\n          -  The use of topical steroids 6 weeks prior to baseline and during the study.\n\n          -  The use of systemic corticosteroids 6 weeks prior to baseline and during the study.\n\n          -  The use of vasodilators 6 weeks prior to baseline or during the study.\n\n          -  The use of \u03b1-adrenergic receptor-blocking agents 6 weeks prior to baseline and during\n             the study.\n\n        Prohibited Medications:\n\n          -  Chronic use (> 14 days) of sulfa drugs, erythromycin, cephalosporins, and quinolones.\n\n          -  The use of tetracycline antibiotics is prohibited.\n\n          -  Use of any acne treatment during the course of the study, including spironolactone.\n\n          -  Chronic use (> 14 days) of NSAIDs.  Chronic use of aspirin at sub-analgesic doses (<\n             325 mg q.d.) may be used by those patient requiring platelet aggregation inhibitor.\n\n          -  Penicillin antibiotics should NOT be used during the course of this trial since the\n             bacteriostatic action of doxycycline may interfere with the bactericidal action of\n             penicillins.\n\n          -  Antacids and vitamins containing aluminum, calcium, or magnesium may impair drug\n             absorption and should be taken at least 1.5 hours before or 3.0 hours after taking\n             study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "150", 
        "firstreceived_date": "July 19, 2002", 
        "id_info": {
            "nct_id": "NCT00041977", 
            "org_study_id": "DERM-303"
        }, 
        "intervention": {
            "intervention_name": "doxycycline hyclate 20 mg twice daily", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "keyword": "Rosacea", 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "University of Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33104"
                    }, 
                    "name": "Beer and Houck/Florida Dermatology Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "University of Louisville"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Milton S. Hershey Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "David Pariser, MD"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041977"
        }, 
        "source": "CollaGenex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CollaGenex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2003"
    }, 
    "geocoordinates": {
        "Beer and Houck/Florida Dermatology Institute": "26.715 -80.053", 
        "David Pariser, MD": "36.851 -76.286", 
        "Milton S. Hershey Medical Center": "40.286 -76.65", 
        "University of Florida": "29.652 -82.325", 
        "University of Louisville": "38.253 -85.758", 
        "University of Miami Medical Center": "25.789 -80.226", 
        "University of Pennsylvania": "39.952 -75.164"
    }
}